Serum markers for type IV collagen and type III procollagen in the myelofibrosis‐osteomyelosclerosis syndrome and other chronic myeloproliferative disorders

1991

APMIS

Lisse I, Hasselbalch, H. & Junker, P. Bone marrow stroma in idiopathic myelofibrosis and other haematological diseases. An immunohistochemical study. APMIS 99: 171-1 78, 1991. Bone marrow stroma was investigated immunohistochemically in 3 1 patients with haematological diseases, mainly idiopathic myelofibrosis (n = 8) and related chronic myeloproliferative disorders (n= 14). The bone marrow from patients with idiopathic myelofibrosis and some CML patients showed marked staining reactions with antibodies against type I11 procollagen (pN collagen), type IV collagen, fragment P1 of laminin and factor VIII. Patients with osteomyelosclerosis had particularly increased collagen content, including both newly deposited type I11 collagen (pN collagen) and mature collagen fibres. As in normal bone marrow, argyrophilic fibres and type 111 collagen displayed a close co-distribution, which was also demonstrated for type IV collagen and laminin. While normal bone marrow sinusoids had discontinuous basement membranes, fibrosing bone marrow was characterized by endothelial cell proliferation and capillarization, with the development of continuous sheets of basement membrane material beneath endothelial cells.

Section: (Apuja-sarkkinen Etsupporting

confidence: 85%

Bone marrow stroma in idiopathic myelofibrosis and other haematological diseases.

Lisse

Hasselbalch

1991

APMIS

“…Idiopathic myelofibrosis (IMF) is a chronic myeloproliferative disorder that features excessive deposition of interstitial and basement membrane collagens in the bone marrow [ 1-31. Recent studies have shown that the serum levels of type I11 collagen [4-91 and type IV collagen [8] metabolites correlate with conventional markers of disease activity in IMF and allied disorders. Hyaluronan (HYA) is a high-molecular-weight polysaccharide consisting of alternating glucosamin and glucuronic acid subunits.…”

Section: Introductionmentioning

confidence: 99%

Circulating hyaluronan in the myelofibrosis/osteomyelosclerosis syndrome and other myeloproliferative disorders

Hasselbalch¹,

Lisse

et al. 1991

American J Hematol

Self Cite

The serum concentration of hyaluronan (HYA) was determined in 59 patients with various myeloproliferative disorders, including 33 patients with idiopathic myelofibrosis. In 18 patients the serum concentration of the aminoterminal propeptide of type III procollagen (PIIINP) was measured concomitantly. Raised serum HYA levels were seen in patients with active disease compared with age-matched healthy subjects, whereas no significant difference in serum HYA was seen between patients with stable disease and age-matched controls. Serum HYA concentrations correlated significantly with the leukocyte count (rho = 0.38; P less than 0.02) and with the serum concentration of PIIINP (rho = 0.50; P less than 0.001). During cytotoxic treatment, the serum HYA and PIIINP concentrations decreased in concert with declining leukocyte counts. These findings suggest that clonal expansion is accompanied by a bone marrow stromal reaction similar to the repair processes following injury to soft connective tissues. The relatively modest changes in serum HYA with frequent overlaps between patient categories and healthy subjects imply that the clinical utility of single determinations of serum HYA in the present disease groups is restrained. On the other hand, sequential measurements of HYA may provide a reflection of the myeloproliferative process in individual patients.

“…In recent years the aminoterminal propeptide of type 111 procollagen (PIIINP) has been suggested as a seromarker of the fibroproliferative activity in the bone marrow in various myelofibrosing disorders [ 1-61, In crosssectional studies, a significant correlation between the serum concentration of the propeptide and the leucocyte count has been found, indicating a relationship between fibrogenesis and the activity of the clonal myeloproliferation (1,4,5]. This relationship as well as the influence of chemotherapy on serum PIIINP (S-PIIINP) remain to be studied prospectively in a larger series of patients.…”

Section: Introductionmentioning

confidence: 99%

Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: Relation to disease activity and effect of chemotherapy

Hasselbalch¹,

Hørslev‐Petersen

et al. 1990

American J Hematol

Self Cite

The serum concentration of the aminoterminal propeptide of type III procollagen (PIIINP) was measured serially in patients with idiopathic myelofibrosis and other myeloproliferative syndromes. Two different assays were applied, the RIA-gnost assay (Hoechst, Frankfurt, FRG) and a new equilibrium RIA for the N-terminal propeptide of human type III procollagen (Farmos Diagnostica, Oulu, Finland). A positive correlation was found between the results obtained by the two RIA's (rho = 0.90, P less than 0.001). The highest propeptide levels were recorded in patients with idiopathic myelofibrosis, particularly in those with active disease. Elevated serum PIIINP levels decreased during treatment with various cytotoxic drugs, including intensive chemotherapy. By contrast, serum PIIINP was unchanged or increased in patients undergoing interferon alpha-2b therapy. Gel filtration of sera on Sephacryl S-300 column (Pharmacia, Sweden) showed that smaller PIIINP related peptides dominated in healthy subjects and in osteomyelosclerosis with stable disease. Conversely, the relative proportion of intact propeptide increased in accelerating disease stages and acute myelofibrosis. In conclusion, the present study implicates serum PIIINP as a useful indicator of disease activity in idiopathic myelofibrosis. The propeptide also appears to be a sensitive sero-marker of chemotherapy effect on fibrogenesis related to clonal myeloproliferation. Finally, the propeptide is suggested as an early predictor of relapse during cytotoxic therapy.